Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T13:30:33.397Z.
Calculation as of: 2026-10-06T13:30:33.397Z.
Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: adca945f375d0863f0f013440b023eebfab0caffb47005764e85a23fe93f72ce
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2018-09-04.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
EV/EBITDA RATIO AVG TTM
N/A
EV/EBITDA RATIO AVG 3Y
N/A
EV/EBITDA RATIO AVG 5Y
N/A
EV/EBITDA RATIO AVG 10Y
N/A
EV/EBITDA RATIO AVG 15Y
N/A
EV/EBITDA RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Aquestive Therapeutics, Inc.
Market Cap
$579.66M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$583.37M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$589.38M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$568.20M
EV/EBITDA Ratio
N/A
TTM Avg
13.55x
3Y Avg
10.69x
5Y Avg
10.69x
Market Cap
$598.37M
EV/EBITDA Ratio
3.85x
TTM Avg
7.68x
3Y Avg
8.80x
5Y Avg
8.39x
Market Cap
$549.24M
EV/EBITDA Ratio
N/A
TTM Avg
144.36x
3Y Avg
144.36x
5Y Avg
144.36x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | $579.66M | N/A | N/A | N/A | N/A |
| CorMedix Inc. (CRMD)vs › | $578.97M | 1.85x | 5.90x | 15.41x | 15.41x |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $583.37M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $589.38M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $568.20M | N/A | 13.55x | 10.69x | 10.69x |
| OrthoPediatrics Corp. (KIDS)vs › | $595.38M | N/A | N/A | N/A | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $598.37M | 3.85x | 7.68x | 8.80x | 8.39x |
| Immix Biopharma, Inc. (IMMX)vs › | $554.90M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $549.24M | N/A | 144.36x | 144.36x | 144.36x |
| Crescent Biopharma, Inc. (CBIO)vs › | $548.99M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBITDA RATIO |
|---|---|
| 2018-09-04 | 47.02x |
| 2018-08-31 | 47.31x |
| 2018-08-30 | 45.29x |
| 2018-08-29 | 44.61x |
| 2018-08-28 | 42.48x |
| 2018-08-27 | 41.24x |
| 2018-08-24 | 41.77x |
| 2018-08-23 | 42.26x |
| 2018-08-22 | 42.35x |
| 2018-08-21 | 42.04x |
| 2018-08-20 | 42.33x |
| 2018-08-17 | 42.43x |
| 2018-08-16 | 42.67x |
| 2018-08-15 | 43.54x |
| 2018-08-14 | 43.71x |
| 2018-08-13 | 42.84x |
| 2018-08-10 | 41.65x |
| 2018-08-09 | 40.15x |
| 2018-08-08 | 40.15x |
| 2018-08-07 | 40.02x |
| 2018-08-06 | 40.00x |
| 2018-08-03 | 40.02x |
| 2018-08-02 | 40.05x |
| 2018-08-01 | 40.24x |
| 2018-07-31 | 40.10x |
| 2018-07-30 | 40.15x |
| 2018-07-27 | 40.44x |
| 2018-07-26 | 42.06x |
| 2018-07-25 | 42.55x |
